advertisement
Abstract #27492 Published in IGR 12-4
Mirtogenol((registered trademark)) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
Steigerwalt Jr RD; Belcaro G; Morazzoni P; Bombardelli E; Burki C; Schonlau FClinical Ophthalmology 2010; 4: 471-476
Purpose: The dietary supplement Mirtogenol((registered trademark)) was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. Methods: Seventy-nine patients with asymptomatic ocular hypertension were random lyassigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks. Results: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg afterfour weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone(27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments. Conclusions: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost.These promising results warrant further research of Mirtogenol with a larger patient group. (copyright) 2010 Steigerwalt et al, publisher and licensee Dove Medical Press Ltd.
F. Schonlau. Horphag Research (UK) Ltd, Suite 393, 28 Old Brompton Road, South Kensington, London SW7 3SS, United Kingdom. frank@horphag.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
